AI Engines For more Details: Perplexity Kagi Labs You
Muscarinic Acetylcholine Receptor Agonism: Tremorine dihydrochloride acts as an agonist at muscarinic acetylcholine receptors, specifically the M2 and M3 receptor subtypes. Activation of these receptors leads to various physiological responses, including smooth muscle contraction, glandular secretion, and modulation of neurotransmitter release.
Induction of Tremors: Tremorine dihydrochloride is frequently used in scientific research to induce tremors and other motor disturbances in experimental animals, particularly rodents. These tremors are a result of increased cholinergic activity in the central nervous system, leading to dysregulation of motor control circuits and involuntary muscle contractions.
Neuroscientific Research: Tremorine dihydrochloride is valuable as a research tool for studying the neurobiology of tremor disorders and the role of muscarinic acetylcholine receptors in motor control. By inducing tremors in experimental animals, researchers can investigate the underlying mechanisms of tremor generation and potential therapeutic interventions.
Modeling Neurological Conditions: Tremorine dihydrochloride-induced tremors may serve as a model for studying various neurological conditions characterized by tremor, such as Parkinson's disease, essential tremor, and drug-induced tremor. By replicating tremor-like symptoms in animal models, researchers can evaluate the efficacy of potential treatments and gain insights into the pathophysiology of these disorders.
Safety Considerations: While tremorine dihydrochloride is useful for experimental purposes, it is not used therapeutically in medical practice due to its potential to induce tremors and other adverse effects. Careful handling and administration are required to minimize the risk of unintended side effects in research animals.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.2 | 0.2 | |
| Allergies | 0.3 | -0.3 | |
| Allergy to milk products | 0.2 | 0.2 | |
| Alzheimer's disease | 0.2 | 0.2 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | -0.2 | |
| Ankylosing spondylitis | 0.2 | -0.2 | |
| Anorexia Nervosa | 0.2 | -0.2 | |
| Atherosclerosis | 0.2 | 0.2 | |
| Atrial fibrillation | 0.2 | 0.2 | |
| Autism | 0.2 | 0.2 | 0 |
| Bipolar Disorder | 0.2 | 0.2 | 0 |
| Carcinoma | 0.2 | 0.2 | 0 |
| Celiac Disease | 0.2 | -0.2 | |
| Cerebral Palsy | 0.2 | -0.2 | |
| Chronic Fatigue Syndrome | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Colorectal Cancer | 0.2 | 0.2 | |
| Coronary artery disease | 0.2 | 0.2 | |
| COVID-19 | 0.2 | 0.5 | -1.5 |
| Crohn's Disease | 0.2 | 0.2 | 0 |
| deep vein thrombosis | 0.2 | -0.2 | |
| Depression | 0.3 | 0.2 | 0.5 |
| Endometriosis | 0.2 | -0.2 | |
| Functional constipation / chronic idiopathic constipation | 0.2 | 0.2 | |
| gallstone disease (gsd) | 0.2 | 0.2 | |
| hypertension (High Blood Pressure | 0.2 | 0.2 | |
| Inflammatory Bowel Disease | 0.5 | -0.5 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.2 | 0.2 | |
| Liver Cirrhosis | 0.2 | 0.2 | 0 |
| Long COVID | 0.5 | -0.5 | |
| Lung Cancer | 0.2 | -0.2 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Metabolic Syndrome | 0.2 | 0.2 | 0 |
| Mood Disorders | 0.5 | 0.2 | 1.5 |
| Multiple Sclerosis | 0.2 | 0.2 | 0 |
| Multiple system atrophy (MSA) | 0.2 | -0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | -0.2 | |
| Obesity | 0.2 | 0.2 | 0 |
| obsessive-compulsive disorder | 0.3 | 0.3 | |
| Osteoarthritis | 0.2 | -0.2 | |
| Osteoporosis | 0.2 | 0.2 | |
| Parkinson's Disease | 0.2 | -0.2 | |
| Polycystic ovary syndrome | 0.2 | 0.3 | -0.5 |
| Psoriasis | 0.2 | 0.2 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.2 | 0.2 | |
| Rosacea | 0.2 | 0.2 | |
| Schizophrenia | 0.2 | 0.2 | 0 |
| scoliosis | 0.2 | -0.2 | |
| Sleep Apnea | 0.2 | 0.2 | |
| Systemic Lupus Erythematosus | 0.2 | -0.2 | |
| Tic Disorder | 0.2 | 0.2 | |
| Type 1 Diabetes | 0.2 | 0.2 | |
| Type 2 Diabetes | 0.2 | 0.2 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.